Australia's most trusted
source of pharma news
Tuesday, 14 April 2026
Posted 14 April 2026 PM
Regeneron is entering the rapidly growing radiopharmaceutical sector by teaming up with Telix Pharmaceuticals, a collaboration that could bring the Australian company up to $3.057 billion.
Under the strategic radiopharma collaboration, Telix will receive $57 million upfront for access to its radiopharmaceutical manufacturing platform for four initial therapeutic programs.

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.